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Abstract. MicroRNAs (miRNAs) mir15a and let7a are
important regulators of bcl-2, ras and c-myc proteins.
Considering that these miRNAs are commonly altered in
many human cancers and that these proteins are reported
to be altered in oral squamous cell carcinoma (OSCC), we
investigated them in a set of OSCC cases. The miRNAs
as well as the proteins were evaluated in the tumor and
blood of 20 patients by real-time quantitative PCR and
immunohistochemistry, respectively. The expression of
mir15a and bcl-2 proteins in the tumors was not associated
with each other or with tumor staging. On the other hand,
we found reduced expression of this miRNA in the blood of
patients with an advanced stage of OSCC and with lymph node
metastasis. The expression of let7a in the tumor and blood was
not associated with tumor size, lymph node metastasis, tumor
staging and immunoexpression of ras and c-myc proteins. In
conclusion, the present study shows that reduced expression of
mir15a is associated with OSCC staging.
Introduction
MicroRNAs (miRNAs) are small non-coding evolutionarily conserved RNAs which mediate gene expression at
the post-transcriptional level by degrading or repressing
target messenger RNA (mRNA) (1,2). miRNAs are products
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approximately 22 nucleotides long which regulate mRNA
translational by base pairing to partially complementary sites,
predominantly in the 3' untranslated region (3'UTR) (2). Each
miRNA has the potential to regulate many target genes in
humans, modulating the levels of thousands of mRNAs, which
implies that over one third to one half of all protein-encoding
genes in humans are regulated by miRNAs (3). Considering
the important effect of miRNAs on gene expression, it is
not surprising that these small RNAs have been implicated
in the pathogenesis of cancer (4). The expression profiles of
miRNAs are usually altered in many cancers. A reduction in
miRNAs accelerates oncogenic transformation through the
deregulation of target oncogenes (5). Oncogenic miRNAs
have also been described and have been shown to be involved
in the pathogenesis of some tumors. In this case, the increased
transcription of miRNA inactivates a tumor-suppressor gene.
Oral squamous cell carcinoma (OSCC) is one of the most
frequent cancers in the world, and its main risk factors include
smoking and alcohol consumption. This neoplasia results from
multiple genetic events, resulting in damage to signalling pathways and the regulation of the cell cycle. The 5-year survival
rate for cancers of the tongue, oral cavity and oropharynx is
approximately 50% (6). Despite the importance of miRNAs
in human cancer, few studies have attempted to evaluate their
expression in oral cancer (7). In the present study, we selected
two miRNAs (mir15a and let7a) that are commonly altered
in different types of cancer. We also chose these miRNAs as
they regulate the expression of proteins reported to be altered
in OSCC (bcl-2, ras and c-myc). The results showed decreased
expression of mir15a in the blood of patients with advanced
stage OSCC and lymph node metastasis.
Materials and methods
A total of 20 primary tumors and peripheral blood were
obtained from 20 patients with OSCC immediately after
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surgical resection. The average age of the patients was
57 years (range, 37-90 years), and they were predominantly
male. Histological classification was performed according to
the International Histological Classification of Tumors (8) and
the TNM staging system according to the International Union
Against Cancer (UICC).
The tissue samples were collected in RNAholder
(BioAgency, Sao Paulo, Brazil). All samples were collected at
the time of surgery. A section of the lesion was immediately
snap frozen and stored at -80˚C. The other part was fixed
in buffered formalin for histopathological diagnosis.
Histopathological analysis confirmed that each tissue sample
had a >60% tumor cell content. The peripheral blood (4 ml)
was collected immediately after surgical resection of the
primary tumor. The blood was collected in a tube with
anticoagulant (EDTA) and stored at -80˚C until processing.
Fragments of normal oral mucosa and the peripheral blood
of healthy volunteers were collected during non-neoplastic or
preprosthetic surgical procedures and were used as control.
The present study was approved by the local ethics committee,
and a signed informed consent was obtained from all of the
patients as well as the healthy volunteers.
Total RNA was isolated from 25 mg of human frozen
samples and 250 µl of peripheral blood sample in 1 ml of
TRIzol Reagent (Invitrogen Life Technologies, Inc., Carlsbad,
CA, USA), according to the manufacturer's instructions.
The RNA was briefly treated with RNAse-free DNAase I
(Invitrogen Life Technologies), and the cDNA was synthetized
from 1 µg of total RNA using gene-specific stem-loop primers
to miRNA (9) (TaqMan MicroRNA RT; Applied Biosystems,
Foster City, CA, USA). The expression of miRNA was profiled
using a real-time quantitative TaqMan assay (TaqMan®
MicroRNA Assays; Applied Biosystems) in a Step-One
real-time PCR 48-well plate (Applied Biosystems). The 20 µl
total reaction included 2 µl of cDNA, 2X TaqMan Universal
PCR master mix (no EmpErase UNG) and probe mix of the
TaqMan MicroRNA Assay protocol (Applied Biosystems).
The PCR triplicate reaction was performed in a 48-well
optical plate at 95˚C for 10 min, followed by 15 sec at 95˚C
and 1 min at 60˚C for 40 cycles. The mean of the threshold
cycle (Ct), defined as the fractional cycle number at which
the fluorescence passes the fixed threshold, was determined
using default threshold settings. Relative gene expression was
calculated using the 2-ΔΔCt method (Applied Biosystems User
Bulletin No. 2) as previously described (10), and the expression data were normalized with endogenous miRNA RNU48,
U47 and RNU44. The data were presented as log10 of the
relative quantity of target miRNA normalized to endogenous
miRNA and relative to a calibrator sample. As calibrator we
used a pool of normal oral tissues for the tumoral tissues, and
blood samples of healthy individuals for the blood of patients
with OSCC.
The total RNA input ranged from 6.25 to 100 ng. The
results showed that the method was able to detect miRNA
in as little as 10 or 100 ng of total RNA. As the amount of
cDNA was decreased, the amplification started later, giving a
higher Ct. We used 10 ng of RNA for all experiment to obtain
a good balance between cDNA economy and an assay of good
quality. For the let7a, the slope value was -3.329 and R2 was
0.979. The mir15a experiments showed a slope value of -3.28

and R2 of 0.987. The endogenous control RNU44, U47 and
RNU48 showed similar values (slope = -3.33 and R2 = 0.981).
The following antibodies were used for immunohistochemical analysis: bcl-2 (diluted 1:20, Clone 124; Dako® Corp.,
Carpinteria, CA, USA), c-myc (diluted 1:75, Clone 3C117;
Santa Cruz® Biotechnology Inc., Santa Cruz, CA, USA) and
h-ras (diluted 1:20, Clone F235; Santa Cruz Biotechnology).
Immunohistochemical stains were performed using the high
sensitive polymer-based system (EnVision; Dako Corp.) with
diaminobenzidine substrate solution as chromogen (Sigma,
St Louis, MO, USA). In the immunohistological analysis,
only sections containing sufficient neoplasic epithelium were
used to assess the antibody reactivity. Two experienced independent pathologists examined multiple fields and scored the
tissue sections for the extent of staining, regardless of staining
intensity (score 0, negative staining; score 1, 0-25% of positive
cells; score 2, 25-50% of positive cells; score 3, >50% of positive cells).
Statistical methods. Non-parametric Spearman correlation
coefficients were used to assess the association between
continuous variables. The non-parametric Mann-Whitney test
was used to compare two groups of cases on one variable.
Statistical analyses were performed using BioStat 4.0 software
(Optical Digital Optical Technology, Belém, Brazil), and a
p-value ≤0.05 was considered statistically significant.
Results
The gender, age, location, TNM, tumor staging and miRNA
expression in the tumor and blood of patients with OSCC are
presented in Table I.
Expression of mir15a in OSCC. Compared to normal oral
tissues, increased expression of mir15a was found in 14 cases
of OSCC (87.5%). The median level of mir15 expression in the
tumors of early stages (I, II and III) was not different when
compared with that of tumors in an advanced stage (Table I).
No statistical difference was found according to tumor size
and lymph node metastasis.
Expression of mir15a in the blood samples. While decreased
expression of mir15a was found in the blood samples of
6 patients with OSCC (35.2%), increased expression was
observed in 11 cases (64.8%) (Table I). All of the cases with
decreased expression of mir15a in the blood were OSCC cases
in an advanced stage (stage IV) with lymph node metastasis.
Therefore, reduced expression of this miRNA in the blood
was associated with an advanced stage of the tumor (p=0.006)
(Fig. 1) and with lymph node metastasis (p=0.010) (Fig. 2).
The levels of mir15a expression in the blood samples of
patients with OSCC were clearly lower than the levels in the
matched tumor samples (p=0.034).
mir15a and bcl-2 protein expression. Only sections containing
sufficient neoplasic epithelium were examined. Positive
labeling for bcl-2 protein was observed in 4 samples of OSCC
(score 1). The expression of mir15a in the cases with negative immunostaining for bcl-2 was not statistically different
compared to the lesions with positive labeling.
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Table I. Gender, age, location, TNM, tumor staging, let7a and mir15a miRNA expression in the blood and tumors of oral
squamous cell carcinoma patients included in the study.
Case

Gender	Age	Location	TNM	

Stage	Let7a expressiona
-------------------------------						
Blood	Tumor

mir15a expressiona
---------------------------------------Blood	Tumor

1	M	
2	M	
3
F
4	M	
5	M	
6
F
7	M	
8
F
9
M
10	M	
11	M	
12	M	
13	M	
14	M	
15
F
16	M	
17	M	
18	M	
19	M	
20	M	

0.490
10.446
0.129
0.462
1.543
0.546
0.249
0.005
2.084
0.599
3.693
2.319
4.084
4.029
0.429
2.134
121.275
3.517

56	Retromolar trigone	T2N2M0	IV	
55
Floor of the mouth	T3N0M0	III	
61	Tongue	T4N2M0	IV	
49
Floor of the mouth	T3N0M0	III	
51	Tongue	T2N0M0	II	
68	Tongue	T4N1M0	IV	
56	Retromolar trigone	T4N0M0	IV	
41	Tongue	T3N0M0	III	
59
Gingiva + floor of the mouth T4N0M0
IV
55	Retromolar trigone	T4N1M0	IV	
44
Floor of the mouth	T4N0M0	IV	
37
Floor of the mouth	T4N0M0	IV	
59	Tongue	T2N0M0	II	
74
Gingiva	T4M0M0	IV	
50
Floor of the mouth	T2N0M0	II	
73	Retromolar trigone	T2N0M0	II	
72
Floor of the mouth	T4N3M0	IV	
61
Floor of the mouth	T2N0M0	II	
68	Tongue + retromolar trigone	T3N0M0	III	
73
Gingiva	T4N0M0	IV	

1.119
0.864
0.784
4.662
3.969
0.020
0.595
0.003
0.557
0.001
0.079
6.545
4.509
0.934
0.488
4.415
3.236
8.196

0.512
2.506
4.075
0.713
1.289
0.004
0.782
1.221
7.705
41.144
2.370
1.448
0.634
1.265
0.403
0.388
8.066
41.087
1.495
34.967

3.944
12.554
3.144
3.683
5.579
1.965
0.032
18.466
1265.276
14.739
1.568
3.498
0.220
162.979
226.736
5.499
325.293

2

a -ΔΔCt

Figure 1. Relative quantification (2-ΔΔCt) of mir15a in oral squamous cell
carcinoma stage I-III compared to stage IV. Decreased mir15a expression was
noted in the tumors with stage IV (p=0.006).

Expression of let7a in OSCC. While higher levels of let7a
expression in OSCC compared to normal oral mucosa were
found in 13 cases (61.9%), decreased expression was found
in 18 cases (38.1%) (Table I). The expression of let7a was
not associated with tumor size, lymph node metastasis and
tumor stage.

Figure 2. Relative quantification (2-ΔΔCt) of mir15a in oral squamous cell
carcinoma without lymph node metastasis (N-) compared with positive
lymph node metastasis (N+). Decreased mir15a expression was noted in the
N+ cases (p=0.010).

Expression of let7a in blood samples. Decreased expression of
let7a was found in the majority (18 out of 20) of blood samples
of patients with OSCC (Table I). The expression of let7a in
the blood was significantly lower than that in the matched
tumors. No statistical association was found regarding lymph
node metastasis and tumor size. No statistical correlation was
found between the expression of let7a and mir15a.
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Let7a and c-myc or ras protein expression in OSCC. Most
of the samples (14 out of 20) presented moderate (score 2) or
strong (score 3) c-myc expression. The expression of let7a in
the cases with c-myc score 2 was not statistically different
when compared to the expression of let7a in the cases with
c-myc score 3. All cases with decreased expression of let7a
showed strong positive staining for c-myc, but this association
was not statistically significant.
Most of the samples were positive for the ras protein. The
expression of let7a in the cases with ras staining score 1 was
not statistically different when compared to the expression of
let7a in the cases with ras staining score 3.
Expression of bcl-2, c-myc and ras regarding tumor staging.
No relationship was observed between expression of bcl-2,
c-myc and ras with tumor staging.
Discussion
Tran et al (11) investigated 261 mature miRNA genes in nine
head and neck cancer cell lines using an oligonucleotide
array platform. The cell lines were from carcinomas of the
hypopharynge, tongue, larynx and tonsil. The authors found
overexpression of 33 miRNAs, and 22 exhibited low expression. Another study showed that cancer cell lines from head
and neck overexpress miR-205r (12). One important limitation
of these studies was the use of cancer cell lines for investigation. miRNA from cancer cell lines may not show the same
profile as the original tumor. According to some researchers,
in vitro growth conditions including the inclusion of synthetic
medium and fetal bovine serum may have an effect on miRNA
expression patterns in human tumor cell lines (13).
Evidence suggests that miRNAs may control cancer
development, or at least play a critical role in the pathogenesis
through regulation of cell growth and apoptosis. The association of miRNAs with the expression of important oncogenes
such as bcl-2, c-myc and ras supports a key role for these small
molecules in human cancer.
Diminished or loss of expression of mir15a has been
demonstrated in chronic lymphocytic leukemia and in
prostate cancer (14). The 3'UTR of the bcl-2 transcript has
potential binding sites for mir15a and mir16-1, and these
miRNAs have the ability to downregulate the anti-apoptotic
protein bcl-2 (15). Furthermore, the expression of this miRNA
induces apoptosis in leukemia cell lines. Considering that
OSCC shows altered expression of bcl-2 (16) we attempted
to investigate the association between this miRNA and its
target protein, together with its impact on clinical staging. We
observed increased expression of mir15a in most of the OSCC
cases, which may be associated with the negative staining
found for bcl-2 in many of the samples studied. However, we
did not observe any statistical significant association between
this miRNA and this anti-apoptotic protein. The lack of
association between both may be explained by other proteins
or regulators of bcl-2 apart from mir15a which are also able to
influence bcl-2 expression. For example, bcl-2 expression may
be regulated by tyrosine kinase inhibitors that can regulate
apoptosis and inhibit bcl-2 expression. bcl-2 phosporylation
may be another regulatory mechanism of bcl-2 protein
expression (17).

We did not find an association between mir15a expression in OSCC and tumor staging, tumor size and lymph node
metastasis. Notably, reduced expression of mir15a was found
in the blood of patients with lymph node metastasis or in
advanced clinical staging (stage IV) compared to stages I, II
and III. Loss of heterozygosity of 13q.14.3, the same locus of
mir15a, was previously reported in OSCC and was correlated
with lymph node metastasis (18). These data further support
the importance of chromosome 13q in the pathogenesis of
OSCC. These findings also suggest that the expression of this
tumor-supressor miRNA in the blood of patients with OSCC
may also be useful in tumor staging.
Considering the methodology used in the present study,
it is not possible to know the origin of mir15a found in the
blood. The possible sources of this miRNA include circulating
leukocytes, cancer cells or their products that have reached the
circulation. Although the decreased expression of this miRNA
may have an impact in the expression of bcl-2 in potentially
metastatic cancer cells in the blood, this hypothesis needs to
be tested.
We did not find an association between let7a expression
and OSCC staging. Reduced expression of let7a was significantly associated with shortened postoperative survival in
patients with lung cancer. Furthermore, let7a overexpression
results in the inhibition of lung cancer cell growth (19), as well
as the growth of human colon cancer cells (20). Recent studies
have shown an association between miRNA expression, such
as let7 and mir-205, and the severity and poor survival in
patients with head and neck cancer (21,22). Our data did not
confirm a tumor-suppressor role for let7a in the pathogenesis
of OSCC.
Let7 miRNA negatively regulates the expression of ras and
c-myc by targeting their mRNAs for translation repression
(23). In lung cancer, reduced levels of let7 were observed
together with increased expression of the ras protein (19).
The presence of any ras variant was significantly associated
with poor prognosis in squamous cell carcinoma of the
head and neck, and prognosis was worse among cases of
oral cancer (24). Studies of ras expression in squamous cell
carcinoma of the head and neck have indicated that amplified
ras promotes growth, and the presence of the ras protein has
been associated with late stage tumors and increased tumor
size (25). Most of the OSCC cases in the present study were
positive for the ras protein, but the expression of this protein
was not associated with let7 expression or with tumor size or
lymph node metastasis.
Overexpression of c-myc has been observed in 20-40%
of OSCC cases. Overexpression of c-myc provides changes
in the regulation of many genes and contributes to malignant
transformation (26). In our study, we observed moderate or
strong c-myc expression in most of the samples studied. The
amplification status of the myc gene has often been studied
in parallel with ras. H-ras mutations have been described
in OSCC, but the exact mechanism accounting for ras
overexpression is unknown, and its association with existing
prognostic factors is still unclear. A high level of c-myc
expression is associated with shortened overall survival, tumor
size and clinical stage (26,27). In our study no relationship was
found between c-myc protein and tumor staging. As we did
not find an association between let7a expression with ras or
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c-myc protein immunolocalization, other genetic or epigenetic
alterations may be more relevant to the expression of these
oncogenes in OSCC.
Although the findings here reported are informative, the
phenomenon of genomic convergence (clonal adaptation)
should be considered in the critical analysis of the data.
According to this theory, early stage tumors are karyotypically
heterogeneous, while late stage tumors are often found to be
karyotypically homogeneous due to selection pressures (28).
Therefore, it is not possible to know which of the lesions
included in the analysis were before, during or after genomic
convergence. Despite the limited number of samples, the
present study shows that reduced expression of mir15a in the
blood is associated with OSCC staging.
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